ArticleThe American journal of gastroenterology2016
Editorial: Statins for Inflammatory Bowel Disease: Expanding the Scope of Prevention.
Article in The American journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 8 citations in OpenAlex.
- Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2020Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In addition to cholesterol depletion, statins also significantly decrease systemic inflammation as measured by C-reactive protein. In this issue of American Journal of Gastroenterology, Ungaro et al. present their results on the associations between statin prescriptions and risk of Crohn's disease (CD) and ulcerative colitis (UC). Using a national medical claims and pharmacy database created by Symphony Health Solutions LLC (SHA), they show that any use of statin is protective against diagnosis of CD and UC. The protective effect against CD appears strongest among older populations (>60 years old). These findings offer intriguing insights into inflammatory pathways that could be modulated by cholesterol lowering drugs. In addition, if replicated in other cohorts, these results provide further rationale for investigating the use of statins in broader preventive efforts, including healthy patients at risk of developing inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.